P/B
1,4
SIGA Technologies
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
$224.9M
Market Cap • 11/10/2026
1995
(31 years)
Founded
1997
(29 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,3
EPS
—
Market Cap
Market Cap
224,9M
EV
108,5M
EV/Revenue
2,1
EV/EBITDA
-15,9
EV/EBIT
-14,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,3%
Total Yield
0,3%
Dividend Yield 5Y
8,9%
Payout
6325,2%
Retained Earnings
-80,9M
Profitability
Gross Margin
54%
EBITDA Margin
—
EBIT Margin
—
Net Margin
1,3%
D&A/EBITDA
0%
R&D/Revenue
30,6%
Capex/Revenue
0,1%
Capex/D&A
6,7%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
0,8%
% Goodwill
0,5%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-1,4%
CAGR Net Income 5Y
-47%
CAGR EPS 5Y
-100%
Leverage
N.D./EBITDA
17
Debt/Equity
0%
Current Ratio
24,6
Quick Ratio
17,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!